Elai Davicioni

Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival

This study quantifies cancer stemness in prostate cancer across progression stages, showing its association with therapy resistance, poor survival, and lineage plasticity.

Deep phenotyping of the prostate tumor microenvironment reveals molecular stratifiers of relapse and links inflammatory chemokine expression to aberrant metabolism

The paper identifies molecular signatures in prostate cancer that link inflammatory chemokine expression to metabolic changes and relapse risk.

Genome-wide CRISPR screens identify PTGES3 as a novel AR modulator

This study uses CRISPR screens to identify PTGES3 as a novel modulator of AR protein levels and function in prostate cancer, showing its role in therapy resistance.

MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

This study shows MYC overexpression disrupts AR transcriptional pause release, promoting aggressive prostate cancer progression.

Personalized in-silico drug response prediction based on the genetic landscape of muscle-invasive bladder cancer

The paper presents an automated workflow for in-silico drug response prediction in bladder cancer using multi-omic profiles, identifying personalized treatment options for most patients.

Deep Genomic Signature for early metastasis prediction in prostate cancer

This study introduces DGS, a method combining denoising autoencoders and transfer learning to predict prostate cancer metastasis using both labelled and unlabelled gene expression data, achieving higher accuracy than existing signatures.